Roivant Sciences raises ~$200M via registered direct offering of 19.6M shares at $10.21

Roivant Sciences Ltd.

Sold 19,600,685 common shares at $10.21 each for aggregate gross proceeds of ~$200.1 million.
Net proceeds to be used for investment into subsidiary Immunovant, Inc. and for working capital and general corporate purposes.
Offering made pursuant to prospectus supplement under effective shelf registration statement (Form S-3).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Roivant Sciences Ltd. entered into Purchase and Sale Agreements with certain institutional investors valued at aggregate gross proceeds of approximately $200.1 million (effective 2023-09-26).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: aggregate gross proceeds of approximately $200.1 million
Effective: 2023-09-26

Exact text from the filing

On September 26, 2023, Roivant Sciences Ltd. (the “Company”) entered into common share purchase and sale agreements (collectively, the “Purchase and Sale Agreements”) with certain institutional investors, pursuant to which the Company agreed to issue and sell an aggregate of 19,600,685 of the Company’s common shares

View on SEC.gov

198 material agreements filed in the last 30 days. Browse all material agreements →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-046010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.